| Arrhythmogenic Right Ventricular Dysplasia |
ER-α (ESR1) |
4
|
2.71 (2.09, 3.51) |
3.1E-12 |
5/8 |
Atrial Fibrillation (19860128, 19860128) |
strong |
|
|
|
|
|
|
Coronary Heart Disease (20153472) |
|
|
|
|
|
|
|
Sudden cardiac death (21658281) |
|
|
GR (NR3C1) |
4
|
2.39 (1.84, 3.11) |
1.03E-11 |
5/8 |
Coronary Heart Disease (19783104) |
weak |
|
P300 |
4
|
1.75 (1.31, 2.37) |
5.9E-05 |
5/8 |
Myocardial Infarction (21737953) |
weak |
|
GATA3 |
4
|
2.02 (1.56, 2.63) |
3.89E-08 |
5/8 |
Heart Development (18955134) |
weak |
|
c-Jun (JNK) |
4
|
1.74 (1.32, 2.31) |
2.96E-05 |
5/8 |
Myocardial Infarction via K+ channel regulation (20518594) |
strong |
|
|
|
|
|
|
Myocardial Infarction (21324895) |
|
|
CEBPB |
4
|
1.92 (1.34, 2.83) |
0.000141 |
5/8 |
Chronic Heart Failure (12601168) |
weak |
|
STAT3 |
4
|
2.41 (1.79, 3.27) |
2.96E-10 |
5/8 |
Ventricular Arrhythmias and Contractile Dysfunction (22082679) |
strong |
|
|
|
|
|
|
Atrial Fibrillation (18774104) |
|
|
JunD |
4
|
1.74 (1.29, 2.37) |
0.00011 |
5/8 |
Cardiac hypertrophy and Heart failure (15655111) |
weak |
|
|
|
|
|
|
Chronic Heart Disease (9136081) |
|
|
STAT1 |
4
|
1.68 (1.29, 2.19) |
9.01E-05 |
5/8 |
Atrial Fibrilation (18774104) |
strong |
|
|
|
|
|
|
Long QT Syndrome (17490620) |
|
| Breast Cancer |
E2F6 |
2
|
2.29 (1.76, 2.98) |
1.21E-10 |
62/608 |
Regulation of Tumor Suppressor (ARHI) in BC |
weak |
|
|
13
|
1.67 (1.31, 2.13) |
1.54E-05 |
26/608 |
|
|
|
|
46
|
1.75 (1.41, 2.18) |
1.91E-07 |
28/608 |
|
|
|
CHD2 |
2
|
2.23 (1.72, 2.88) |
6.7E-10 |
62/608 |
Mammary tumor modifier (17557176) |
strong |
|
|
13
|
1.82 (1.43, 2.32) |
8.28E-07 |
26/608 |
Gastric and Colorectal Cancer (21447119) |
|
|
|
|
|
|
|
Colon Cancer Biomarker (17390049) |
|
|
NFYA |
2
|
2.78 (2.14, 3.60) |
9.24E-15 |
62/608 |
E2F-1 Regulation (12697671) |
weak |
|
|
|
|
|
|
Estrogen Regulation (15224348) |
|
|
IRF1 |
2
|
2.34 (1.8, 3.05) |
3.57E-11 |
62/608 |
Resistance to endocrine therapy in Breast Cancer Treatment (22295238) |
strong |
|
|
46
|
2.91 (2.33, 3.65) |
8.9E-23 |
28/608 |
Therapy resistant breast tumors (20457620) |
|
|
|
|
|
|
|
Commonly mutated/rearranged in breast cancers (19697121, 17498560) |
|
|
|
|
|
|
|
Differentially expression in breast tissue >(16241857) |
|
|
HEY1 |
2
|
2.17 (1.63, 2.92) |
1.7E-08 |
62/608 |
Target of Notch signaling (18469855) |
weak |
|
|
13
|
2.5 (1.9, 3.33) |
1.39E-12 |
26/608 |
|
|
|
|
46
|
2.2 (1.73, 2.81) |
8.77E-12 |
28/608 |
|
|
|
E2F1 |
2
|
3.31 (2.53, 4.31) |
8.36E-18 |
62/608 |
Tumor cell growth (22205655) |
strong |
|
|
13
|
2.58 (1.99, 3.33) |
1.27E-12 |
26/608 |
E2F1-dependent drug efficacy in breast cancer treatment (22185819, 20215421) |
|
|
|
154
|
3.78 (2.62, 5.43) |
1.61E-12 |
26/608 |
Breast cancer treatment (21573702, 21479363) |
|
|
|
|
|
|
|
Prognostic breast cancer marker (21453498, 20410059) |
|
| Acquired Immunodeficiency Syndrome |
BATF |
320
|
3.11 (2.24, 4.35) |
4.23E-13 |
8/40 |
Inhibits T cell function in HIV (20890291) |
strong |
|
NFKB |
320
|
2.53 (1.77, 3.67) |
3.04E-08 |
8/40 |
HIV use of NFKB pathway (11160127) |
strong |
|
|
|
|
|
|
NFKB binds HIV TAR-RNA (22352910) |
|
|
BCL11A |
320
|
2.72 (1.99, 3.72) |
2.02E-10 |
8/40 |
Represses HIV-1 gene transcription (15849318) |
weak |
|
MEF2C |
320
|
2.19 (1.55, 3.07) |
8.2E-06 |
8/40 |
Misregulated in HIV-associated dementia (21170291) |
weak |
|
IRF4 |
320
|
2.63 (1.92, 3.61) |
4.01E-10 |
8/40 |
Regulates anti-HIV gene (21078663) |
strong |
|
|
|
|
|
|
Expression associated in HIV-related lymphomas (11157493) |
|
| Thrombocytopenia |
p300 (CREBBP) |
123
|
2.29 (1.5, 3.38) |
8.9E-05 |
5/36 |
Polymorphisms in p300 associated with thrombocytopenia (18684867) |
strong |
|
Fos |
123
|
2.02 (1.47, 2.75) |
1.03E-05 |
5/36 |
PDGF (c-Fos regulator) knockouts induce thrombocytopenia (12670444) |
weak |
|
GATA1 |
123
|
1.87 (1.38, 2.53) |
2.51E-05 |
5/36 |
GATA1 knockout mice develop thrombocytopenia (10216081) |
strong |
